|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The sodium-glucose cotransporter 2 (SGLT2) inhibitor empagliflozin was recently reported to reduce heart failure-associated hospitalizations and cardiovascular mortality amongst individuals with type 2 diabetes at high cardiovascular risk.
|
28391552 |
2017 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review explores the effects of pharmacologic SGLT2 inhibitors' use in cardiac function and discusses the potential role of this class of medication as a treatment for HF.
|
29704192 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
These observations raise the possibility that SGLT2 inhibitors could reduce morbidity and mortality in patients with established heart failure, including those without diabetes.
|
31584231 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sodium-glucose cotransporter 2 (SGLT2) inhibitors are drugs for diabetes and might prevent heart failure.
|
31105148 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expert opinion: DECLARE-TIMI 58 is the longest (4.2 years of follow up), largest (>17,000 participants) and most inclusive (only 41% of individuals with established atherosclerotic cardiovascular disease) CVOT raising the debate towards SGLT2 inhibitor therapy in primary prevention and the potential use of these drugs also in patients with HF without T2DM and other subpopulations.
|
30920851 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although certain T2D medication use in patients with HF appeared consistent with evidence (less use of thiazolidinediones), others appeared contrary to evidence (less use of metformin and SGLT2 inhibitors).
|
30015065 |
2018 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The rate of HF associated with DPP4is was moderated when they were used in combination with SGLT2 inhibitors.
|
29549573 |
2018 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
While little is yet known about SGLT subtype 1, SGLT2 inhibitors have demonstrated to significantly reduce cardiovascular mortality and heart failure hospitalizations.
|
31277431 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent large clinical trials on sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists, with the aim of verifying cardiovascular safety, have revealed that these medications have a preventative advantage on adverse cardiovascular outcomes, including worsening of heart failure and deterioration of nephropathy, in patients with type 2 diabetes (T2D).
|
31440988 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
While dipeptidyl peptidase-4 (DPP-4) inhibitors exhibited increased heart failure hospitalization in the SAVOR-TIMI 53 trial evaluating saxagliptin and in the secondary analysis of the EXAMINE trial for alogliptin, the effects of glucagon-like peptide-1 (GLP-1) analogs and sodium-glucose co-transporter-2 (SGLT2) inhibitors on CV outcomes in diabetes have largely been positive.
|
30767126 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mediators that were identified support existing and novel hypothesized mechanisms for the prevention of heart failure with sodium glucose cotransporter 2 inhibitors.
|
31676303 |
2020 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Robust data from stable outpatient cohorts indicate that the SGLT2 inhibitors are associated with clinically meaningful reductions in major adverse cardiovascular events, lower rates of hospitalization for heart failure, and a reduction in major kidney outcomes There is however a lack of information on how to initiate and manage SGLT2 inhibitors in an acute in-patient setting.
|
31804229 |
2020 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
To assess the effect of SGLT2 inhibitors when used in combination with a loop diuretic, the RECEDE-CHF (Renal and Cardiovascular Effects of SGLT2 inhibition in combination with loop Diuretics in diabetic patients with Chronic Heart Failure) trial is a single-centre, randomised, double-blind, placebo-controlled, cross-over trial conducted in a secondary care setting within NHS Tayside, Scotland.
|
29042392 |
2017 |
|
Congestive heart failure
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Recently, the EMPA-REG OUTCOME trial revealed that empagliflozin, an inhibitor of the sodium-glucose cotransporter 2 (SGLT2), substantially reduced the risk of hospitalization for heart failure, death from cardiovascular causes, and all-cause mortality in patients with type 2 diabetes mellitus at high cardiovascular risk.
|
29016751 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The SGLT-2 inhibitors have opened a new perspective for clinicians treating patients with T2D and established CV disease in light of their 'pleiotropic' effects, specifically on heart failure, while GLP-1RAs seem to present more favourable effects on atherosclerotic events.
|
30888088 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Unraveling the mechanisms behind the beneficial actions of SGLT2 inhibitors may not only contribute to a better understanding of the pathophysiology of cardiovascular diseases but also enable repurposing of gliflozins to improve the routine management of HF patients with or without T2D.
|
31721613 |
2020 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
For the sodium-glucose cotransporter-2 (SGLT2) inhibitor class, the DECLARE-TIMI 58 study (of dapagliflozin) clearly indicates strong protection for heart failure in those with CVD, and probably in those with no prior CVD.
|
30607467 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
The SGLT2 inhibitor empagliflozin was shown to reduce HF admissions and cardiovascular mortality in patients with prior cardiovascular disease including HF.
|
27653447 |
2017 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, novel drugs that have received interest in HF include angiotensin receptor blocker-neprilysin inhibitor (ARNi) and sodium glucose cotransporter 2 (SGLT-2) inhibitors, whose favorable cardiovascular profile has been at least partly attributed to their effects on metabolism.
|
30149104 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on the available evidence, we conclude that SGLT-2 inhibitors represent an evidence-based therapeutic option for the primary prevention of heart failure hospitalization and secondary prevention of CVD in patients with T2DM, and should be considered early on in the treatment algorithm for patients with multiple risk factors, or those with established CVD.
|
31264765 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
This may help provide important clues into the mechanism of benefit of SGLT2 inhibitors in clinical trials and provide a translational framework for the ongoing large studies of SGLT2 inhibitors in the treatment of heart failure.
|
30265814 |
2018 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
At the present time, SGLT2 inhibitors are indicated for the treatment of type 2 diabetes; however, the results of ongoing trials in participants with heart failure but without diabetes are eagerly awaited.
|
31400090 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to determine whether empagliflozin (EMPA), an SGLT2 inhibitor, has a protective role in HF without diabetes.
|
31456369 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, there is growing evidence to illustrate the overall safety profile of this class of agents and support the benefit-risk profile of SGLT2 inhibitors as a preferred option following metformin monotherapy failure, with respect to both kidney disease progression and heart failure outcomes.
|
31410711 |
2019 |
|
Congestive heart failure
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent cardiovascular outcomes trials (CVOTs) have also shown that relative risk reductions in cardiovascular outcomes were observed with SGLT2 inhibition both in patients with current and prior heart failure.
|
31741439 |
2019 |